A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation

Nature Communications

Volumn 6, Issue , 2015, Pages

  Tomita, Saori ^a,b   Abdalla, Mohamed Osama Ali ^a   Fujiwara, Saori ^a,b   Matsumori, Haruka ^a   Maehara, Kazumitsu ^c   Ohkawa, Yasuyuki ^c   Iwase, Hirotaka ^b   Saitoh, Noriko ^a   Nakao, Mitsuyoshi ^a,d  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; UNTRANSLATED RNA; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; RESVERATROL; STILBENE DERIVATIVE;

CANCER; ESTROGENIC COMPOUND; GENE EXPRESSION; HORMONE; HYBRIDIZATION; PIGMENT; RNA;

ARTICLE; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE CLUSTER; GENE LOCUS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA TRANSCRIPTION; UPREGULATION; ADAPTATION; BREAST TUMOR; CARCINOMA; DEFICIENCY; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ADAPTATION, PHYSIOLOGICAL; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; RNA, UNTRANSLATED; STILBENES;

EID: 84928963426     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7966     Document Type: Article

References (68)

1. Sotiriou, C. & Piccart, M. J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer 7, 545-553 (2007).
2. Ali, S. & Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2, 101-112 (2002).
3. Yager, J. D. & Davidson, N. E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282 (2006).
4. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
5. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J. & Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 47, 4355-4360 (1987).
6. Welshons, W. V. & Jordan, V. C. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur. J. Cancer Clin. Oncol. 23, 1935-1939 (1987).
7. Santen, R. J. et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 12(Suppl 1): S61-S73 (2005).
8. Jeng, M. H. et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139, 4164-4174 (1998).
9. Chan, C. M., Martin, L. A., Johnston, S. R., Ali, S. & Dowsett, M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 81, 333-341 (2002).
10. Martin, L. A. et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 278, 30458-30468 (2003).
11. Martin, L. A., Farmer, I., Johnston, S. R., Ali, S. & Dowsett, M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr. Relat. Cancer 12 (Suppl 1): S75-S84 (2005).
12. Ellis, M. J. et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. J. Am. Med. Assoc. 302, 774-780 (2009).
13. Lonning, P. E. et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 67, 111-116 (2001).
14. Iwase, H. et al. Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. Br. J. Cancer 109, 1537-1542 (2013).
15. Okamoto, I., Otte, A. P., Allis, C. D., Reinberg, D. & Heard, E. Epigenetic dynamics of imprinted X inactivation during early mouse development. Science 303, 644-649 (2004).
16. Hebbes, T. R., Clayton, A. L., Thorne, A. W. & Crane-Robinson, C. Core histone hyperacetylation co-maps with generalized DNase I sensitivity in the chicken beta-globin chromosomal domain. EMBO J. 13, 1823-1830 (1994).
17. Saitoh, N. et al. Structural and functional conservation at the boundaries of the chicken beta-globin domain. EMBO J. 19, 2315-2322 (2000).
18. Stalder, J. et al. Tissue-specific DNA cleavages in the globin chromatin domain introduced by DNAase I. Cell 20, 451-460 (1980).
19. Dixon, J. R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376-380 (2012).
20. Nora, E. P. et al. Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature 485, 381-385 (2012).
21. Nora, E. P., Dekker, J. & Heard, E. Segmental folding of chromosomes: a basis for structural and regulatory chromosomal neighborhoods? Bioessays 35, 818-828 (2013).
22. Bickmore, W. A. & van Steensel, B. Genome architecture: domain organization of interphase chromosomes. Cell 152, 1270-1284 (2013).
23. Geisler, S. & Coller, J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14, 699-712 (2013).
24. Carninci, P. et al. The transcriptional landscape of the mammalian genome. Science 309, 1559-1563 (2005).
25. Ravasi, T. et al. Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome. Genome Res. 16, 11-19 (2006).
26. Djebali, S. et al. Landscape of transcription in human cells. Nature 489, 101-108 (2012).
27. Lee, J. T. Epigenetic regulation by long noncoding RNAs. Science 338, 1435-1439 (2012).
28. Gehm, B. D., McAndrews, J. M., Chien, P. Y. & Jameson, J. L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl Acad. Sci. USA 94, 14138-14143 (1997).
29. Nwachukwu, J. C. et al. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. eLife 3, e02057 (2014).
30. Yoon, D. S. et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am. J. Pathol. 161, 391-397 (2002).
31. Aguilar, H. et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 29, 6071-6083 (2010).
32. Miller, T. W. et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 120, 2406-2413 (2010).
33. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
34. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
35. Kos, M., Reid, G., Denger, S. & Gannon, F. Minireview: genomic organization of the human ERalpha gene promoter region. Mol. Endocrinol. 15, 2057-2063 (2001).
36. Reid, G., Denger, S., Kos, M. & Gannon, F. Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell. Mol. Life. Sci. 59, 821-831 (2002).
37. Kim, T. K. et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 465, 182-187 (2010).
38. Harrow, J. et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 22, 1760-1774 (2012).
39. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002).
40. Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007).
41. rMay, D. et al. Large-scale discovery of enhancers from human heart tissue. Nat. Genet. 44, 89-93 (2012).
42. Ellison-Zelski, S. J., Solodin, N. M. & Alarid, E. T. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol. Cell. Biol. 29, 4949-4958 (2009).
43. Hu, X. F. et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer 55, 873-876 (1993).
44. Dunbier, A. K. et al. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genet. 7, e1001382 (2011).
45. Solier, S. et al. Transcription poisoning by Topoisomerase I is controlled by gene length, splice sites, and miR-142-3p. Cancer Res. 73, 4830-4839 (2013).
46. Eisenberg, E. & Levanon, E. Y. Human housekeeping genes are compact. Trends Genet. 19, 362-365 (2003).
47. King, I. F. et al. Topoisomerases facilitate transcription of long genes linked to autism. Nature 501, 58-62 (2013).
48. Castles, C. G., Oesterreich, S., Hansen, R. & Fuqua, S. A. Auto-regulation of the estrogen receptor promoter. J. Steroid Biochem. Mol. Biol. 62, 155-163 (1997).
49. Jia, H. et al. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA 16, 1478-1487 (2010).
50. Ashe, H. L., Monks, J., Wijgerde, M., Fraser, P. & Proudfoot, N. J. Intergenic transcription and transinduction of the human beta-globin locus. Genes Dev. 11, 2494-2509 (1997).
51. Vallot, C. et al. XACT, a long noncoding transcript coating the active X chromosome in human pluripotent cells. Nat. Genet. 45, 239-241 (2013).
52. Nagano, T. et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 322, 1717-1720 (2008).
53. Schubert, T. et al. Df31 protein and snoRNAs maintain accessible higher-order structures of chromatin. Mol. Cell 48, 434-444 (2012).
54. Hall, L. L. et al. Stable C0T-1 repeat RNA is abundant and is associated with euchromatic interphase chromosomes. Cell 156, 907-919 (2014).
55. Marahrens, Y., Panning, B., Dausman, J., Strauss, W. & Jaenisch, R. Xistdeficient mice are defective in dosage compensation but not spermatogenesis. Genes Dev. 11, 156-166 (1997).
56. Kopczynski, C. C. & Muskavitch, M. A. Introns excised from the Delta primary transcript are localized near sites of Delta transcription. J. Cell Biol. 119, 503-512 (1992).
57. Guil, S. et al. Intronic RNAs mediate EZH2 regulation of epigenetic targets. Nat. Struct. Mol. Biol. 19, 664-670 (2012).
58. Gardner, E. J., Nizami, Z. F., Talbot, Jr C. C. & Gall, J. G. Stable intronic sequence RNA (sisRNA), a new class of noncoding RNA from the oocyte nucleus of Xenopus tropicalis. Genes Dev. 26, 2550-2559 (2012).
59. Jensen, T. H., Jacquier, A. & Libri, D. Dealing with pervasive transcription. Mol. Cell 52, 473-484 (2013).
60. Holst, F. et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 39, 655-660 (2007).
61. Tomita, S. et al. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 100, 1012-1017 (2009).
62. Ooi, A. et al. Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J. Pathol. 227, 8-16 (2012).
63. Magnani, L. et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl Acad. Sci. USA 110, E1490-E1499 (2013).
64. Yaswen, P. & Stampfer, M. R. Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. Int. J. Biochem. Cell. Biol. 34, 1382-1394 (2002).
65. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
66. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
67. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
68. Robinson, M. D. & Smyth, G. K. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics 9, 321-332 (2008).